Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.94M
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
98.5M
-
Shares change
-
-1.32M
-
Total reported value, excl. options
-
$23.3M
-
Value change
-
-$1.45M
-
Put/Call ratio
-
0.04
-
Number of buys
-
40
-
Number of sells
-
-33
-
Price
-
$0.24
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q1 2025
109 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q1 2025.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.5M shares
.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (16.9M shares), NEA Management Company, LLC (15M shares), BlackRock, Inc. (11.4M shares), VANGUARD GROUP INC (8.07M shares), ACORN CAPITAL ADVISORS, LLC (7.31M shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (7M shares), ORBIMED ADVISORS LLC (6.78M shares), UBS Group AG (5.04M shares), GEODE CAPITAL MANAGEMENT, LLC (3.62M shares), and STATE STREET CORP (3.06M shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.